2022 Volume 2 Issue 1 Pages 59-62
The World Health Organization (WHO) has been utilizing Emergency Use Listing (EUL) to expand access to medical products during the COVID-19 pandemic. EUL is a risk-based procedure for assessing and listing unlicensed vaccines, medicine, and in vitro diagnostics. To determine whether Japanese medical products acquired EUL relating to COVID-19, we conducted desk research as a part of a new project. Results showed that thirteen of twenty-eight in vitro diagnostic products were from China and three of ten vaccines on EUL were from India. However, only one vaccine manufactured in Japan was on EUL. A common weakness of Japanese companies in the global public procurement market was a lack of knowledge on qualification systems for medical products. We hypothesized holistic approaches from private companies and systematic supports from public sectors are required for a response to an emergency. These activities could lead to contribute to global health issues through sustainable businesses.